Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Fenretinide oral - Laurent Pharmaceuticals/McGill University

Next Previous
Drug Profile

Fenretinide oral - Laurent Pharmaceuticals/McGill University

Alternative Names: Fenretinide oral - Laurent Pharmaceuticals; LAU-7b

Latest Information Update: 08 Aug 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ortho-McNeil Pharmaceutical
  • Developer Cystic Fibrosis Foundation Therapeutics; Laurent Pharmaceuticals; McGill University
  • Class Antifibrotics; Antineoplastics; Antivirals; Chemopreventatives; Retinoids; Small molecules
  • Mechanism of Action Apoptosis stimulants; Retinoic acid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pseudomonal infections
  • New Molecular Entity No

Highest Development Phases

  • Phase III COVID 2019 infections
  • Phase II Cystic fibrosis
  • Preclinical Pulmonary fibrosis
  • No development reported Pseudomonal infections

Most Recent Events

  • 30 May 2024 Laurent Pharmaceuticals completes the phase II RESOLUTION clinical trials in COVID-2019 infections (Adjunctive treatment) in Canada and USA (PO) (NCT04417257)
  • 17 May 2024 Preclinical trials in Pulmonary fibrosis in Canada (PO) prior to May 2024
  • 17 May 2024 Pharmacodynamics data from preclinical studies in Pulmonary fibrosis presented at the 120th International Conference of the American Thoracic Society (ATS-2024)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top